2026-06-29T02:13:31Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1161172025-03-03T19:44:54Zcom_20.500.14352_14col_20.500.14352_15

Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer Pérez-Regadera Gómez, José Fermín Sánchez-Muñoz, Alfonso De-la-Cruz, Javier Ballestín Carcavilla, Claudio Lora Pablos, David García-Martín, Rosa Alonso-Carrión, Lorenzo Mendiola Fernández, Dionisio César Lanzós González, Eduardo Objectives: To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment. Methods: A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB [71]; IVA [19]; including both epidermoid [86] and adenocarcinoma [14]) were analyzed to determine c-erb-B2 levels by immunohistochemistry (c-erb-B2 antibody; Dako, Glostrup, Denmark). Only c-erb-B2+++ biopsies were considered positive. All patients received pelvic radiotherapy, brachytherapy, and concurrent chemotherapy with 2 different regimens: 48 patients were treated with tegafur (800 mg/d orally) and 88 with tegafur (same doses) plus 5 cycles of weekly cisplatin 40 mg/m/wk intravenously. Results: A total of 32 (23.5%) biopsies were considered c-erb-B2-positive. Three-year and 5-year DFS were 61% and 58% for c-erb-B2-negative patients and 36% and 36% for c-erB2-positive patients, respectively (P = 0.02). Patients were stratified in 4 groups according to their c-erb-B2 status and whether they received cisplatin. The group of patients with c-erb-B2 overexpression that did not receive platinum treatment had a higher rate of pelvic relapse (P < 0.0001), associated with a decreased DFS (P = 0.0014). Conclusions: c-erb-B2 overexpression may imply a poor prognosis for patients with advanced CC. Treatment with cisplatin-based radiochemotherapy improved outcome in these patients. 2025-01-27T07:30:00Z 2025-01-27T07:30:00Z 2025-01-27T07:30:00Z 2010-01 journal article https://hdl.handle.net/20.500.14352/116117 1048-891X 10.1111/igc.0b013e3181ad3e11 eng Pérez-Regadera J, Sánchez-Muñoz A, De-la-Cruz J, Ballestín C, Lora D, García-Martín R, Alonso-Carrión L, Mendiola C, Lanzós E. Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer. Int J Gynecol Cancer. 2010 Jan;20(1):164-72. doi: 10.1111/IGC.0b013e3181ad3e11. PMID: 20057287. http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 International BMJ Publishing Group